v3.25.1
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2020
USD ($)
Program
Oct. 31, 2018
Program
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
2018 Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of licensed product | Program   5            
Non-refundable upfront payment received     $ 50,000,000   $ 50,000,000      
Amended Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Research term 7 years              
Number of licensed product | Program 15              
Non-refundable upfront payment received     125,000,000          
Milestone payments receivable $ 410,000,000              
Temporary equity, par value 125,000,000              
Research extension fee             $ 24,000,000 $ 24,000,000
Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Temporary equity, par value $ 20,000,000              
Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Transaction price allocated to performance obligation     199,000,000          
Short-term deferred revenue     19,500,000     $ 17,600,000    
Long-term deferred revenue     37,500,000     $ 44,800,000    
Collaboration Revenue [Member] | Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer liability, revenue recognized     $ 5,400,000 $ 6,500,000